1. Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma
   Xiao-Wei Wang et al, 2024, World Journal of Gastrointestinal Oncology CrossRef
2. Inferring the Functional Effect of Gene-body H3K79me2 Signals in Normal Samples on Gene Expression Changes: A Potential Susceptibility Marker in Chronic Myelogenous Leukemia
   Lu-Qiang Zhang et al, 2023, Current Bioinformatics CrossRef
3. BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia
   Lena Schmidlechner et al, 2024, Oncology Letters CrossRef
4. AMAR-seq: Automated Multimodal Sequencing of DNA Methylation, Chromatin Accessibility, and RNA Expression with Single-Cell Resolution
   Xi Zeng et al, 2024, Analytical Chemistry CrossRef
5. Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line
   Yalda Hekmatshoar et al, 2023, Advances in Medical Sciences CrossRef
6. Global DNA Methylation analysis of imatinib resistant and sensitive K562 cells
   Yalda Hekmatshoar, 2024, Ege Tıp Bilimleri Dergisi CrossRef
7. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
   Meike Kaehler et al, 2023, Precision Medicine CrossRef
8. Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
   Meike Kaehler et al, 2023, Frontiers in Oncology CrossRef